Non-responders to phosphodiesterase type 5 inhibitors: is there a second chance?

Journal of Men's Health and Gender

Volumn 3, Issue 4, 2006, Pages 342-349

  Hatzimouratidis, Konstantinos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Drug therapy; Erectile dysfunction; Penis; Phosphodiesterase inhibitors; Treatment failure

Indexed keywords

PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; TESTOSTERONE; VARDENAFIL;

CHRONIC DRUG ADMINISTRATION; CLINICAL PRACTICE; COUNSELING; DECISION MAKING; DIZZINESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SUBSTITUTION; ERECTILE DYSFUNCTION; FACTORIAL ANALYSIS; HUMAN; HUMAN NEEDS; LITERATURE; LOW DRUG DOSE; OUTCOME ASSESSMENT; PATIENT PARTICIPATION; PATIENT SATISFACTION; PHYSICIAN; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; SEXUAL COUNSELING; SEXUALITY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33750804705     PISSN: 15718913     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmhg.2006.08.007     Document Type: Review

References (41)

1. Braun M., Wassmer G., Klotz T., Reifenrath B., Mathers M., and Engelmann U. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 12 (2000) 305-311
2. Martin-Morales A., Sanchez-Cruz J.J., Saenz de Tejada I., Rodriguez-Vela L., Jimenez-Cruz J.F., and Burgos-Rodriguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 166 (2001) 569-574
3. Papaharitou S., Athanasiadis L., Nakopoulou E., et al. Erectile dysfunction and premature ejaculation are the most frequently self-reported sexual concerns: profiles of 9,536 men calling a helpline. Eur Urol 49 (2006) 557-563
4. Feldman H.A., Goldstein I., Hatzichristou D.G., Krane R.J., and McKinlay J.B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151 (1994) 54-61
5. Aytac I.A., McKinlay J.B., and Krane R.J. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 84 (1999) 50-56
6. Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., and Wicker P.A. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 338 (1998) 1397-1404
7. Hatzichristou D.G., and Pescatori E.S. Current treatments and emerging therapeutic approaches in male erectile dysfunction. BJU Int 88 Suppl 3 (2001) 11-17
8. Lewis R., Bennett C.J., Borkon W.D., et al. Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. Urology 57 (2001) 960-965
9. Steers W., Guay A.T., Leriche A., et al. Assessment of the efficacy and safety of Viagra (sildenafil citrate) in men with erectile dysfunction during long-term treatment. Int J Impot Res 13 (2001) 261-267
10. Hatzichristou D.G. Sildenafil citrate: lessons learned from 3 years of clinical experience. Int J Impot Res 14 Suppl 1 (2002) S43-S52
11. Rutchik S.D., Baudiere M., Wade M., Sullivan G., Rayford W., and Goodman J. Practice patterns in the diagnosis and treatment of erectile dysfunction among family practice physicians. Urology 57 (2001) 146-150
12. Brock G.B., McMahon C.G., Chen K.K., et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 168 (2002) 1332-1336
13. Hatzichristou D.G., Apostolidis A., Tzortzis V., Ioannides E., Yannakoyorgos K., and Kalinderis A. Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracavernous injection for more than 1 year. J Urol 164 (2000) 1197-1200
14. Hellstrom W.J., Gittelman M., Karlin G., et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 61 (2003) 8-14
15. McCullough A.R., Barada J.H., Fawzy A., Guay A.T., and Hatzichristou D. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 60 (2002) 28-38
16. Carson C., Giuliano F., Goldstein I., et al. The 'effectiveness' scale - therapeutic outcome of pharmacologic therapies for ED: an international consensus panel report. Int J Impot Res 16 (2004) 207-213
17. Hatzichristou D., Moysidis K., Apostolidis A., et al. Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur Urol 47 (2005) 518-522
18. Atiemo H.O., Szostak M.J., and Sklar G.N. Salvage of sildenafil failures referred from primary care physicians. J Urol 170 (2003) 2356-2358
19. Barada J. Salvage of 'sildenafil (viagra) failures': benefits of patient and retreatment with sildenafil. Int J Impot Res 13 (2001) S49 [abstract 137]
20. Jiann B.P., Yu C.C., Su C.C., and Huang J.K. Rechallenge prior sildenafil nonresponders. Int J Impot Res 16 (2004) 64-68
21. Gruenwald I., Shenfeld O., Chen J., et al. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol 50 (2006) 134-140
22. Hatzimouratidis K., Moysidis K., Bekos A., Tsimtsiou Z., Ioannidis E., and Hatzichristou D. Treatment strategy for "non-responders" to tadalafil and vardenafil: a real-life study. Eur Urol 50 (2006) 126-132
23. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 1 (2004) 292-300
24. Mirone V., Costa P., Damber J.E., et al. An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol 47 (2005) 846-854
25. Porst H., Giuliano F., Glina S., et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 50 (2006) 351-359
26. McMahon C.G. High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction. Int J Impot Res 14 (2002) 533-538
27. Carson C.C., Hatzichristou D.G., Carrier S., et al. Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int 94 (2004) 1301-1309
28. Hatzichristou D.G., Aliotta P., Auerbach S., et al. Erectile response to vardenafil in men with a history of nonresponse to sildenafil: a time-from-dosing descriptive analysis. Clin Ther 27 (2005) 1452-1461
29. Hatzimouratidis K., and Hatzichristou D.G. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. Drugs 65 (2005) 1621-1650
30. Mulhall J.P., and Montorsi F. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. Eur Urol 49 (2006) 30-37
31. Steers W.D. Viability and safety of combination drug therapies for erectile dysfunction. J Urol 170 (2003) S20-S23
32. Nehra A., Blute M.L., Barrett D.M., and Moreland R.B. Rationale for combination therapy of intraurethral prostaglandin E(1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. Int J Impot Res 14 Suppl 1 (2002) S38-S42
33. Mydlo J.H., Volpe M.A., and Macchia R.J. Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy. Eur Urol 38 (2000) 30-34
34. McMahon C.G., Samali R., and Johnson H. Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol 162 (1999) 1992-1997
35. Shabsigh R. Testosterone therapy in erectile dysfunction and hypogonadism. J Sex Med 2 (2005) 785-792
36. Aversa A., Isidori A.M., Spera G., Lenzi A., and Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 58 (2003) 632-638
37. Kalinchenko S.Y., Kozlov G.I., Gontcharov N.P., and Katsiya G.V. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 6 (2003) 94-99
38. Greenstein A., Mabjeesh N.J., Sofer M., Kaver I., Matzkin H., and Chen J. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed?. J Urol 173 (2005) 530-532
39. Shabsigh R., Kaufman J.M., Steidle C., and Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 172 (2004) 658-663
40. Mulhall J.P., Jahoda A.E., Cairney M., et al. The causes of patient dropout from penile self-injection therapy for impotence. J Urol 162 (1999) 1291-1294
41. Althof S.E. When an erection alone is not enough: biopsychosocial obstacles to lovemaking. Int J Impot Res 14 Suppl 1 (2002) S99-S104